Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportInstrumentation & Data Analysis Track

Kinetic modeling and test-retest variability of the M1 muscarinic acetylcholine receptor PET radiotracer 11C-LSN3172176 in humans

Mika Naganawa, Nabeel Nabulsi, Shu-fei Lin, Lawrence Slieker, Adam Schwarz, Nancy Kant, Hong Gao, Jim Ropchan, David Labaree, Richard Carson and Yiyun Huang
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 499;
Mika Naganawa
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nabeel Nabulsi
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shu-fei Lin
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Slieker
1Eli Lilly and Company Indianapolis IN United States
2Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Schwarz
1Eli Lilly and Company Indianapolis IN United States
2Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy Kant
1Eli Lilly and Company Indianapolis IN United States
2Eli Lilly and Company Indianapolis IN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hong Gao
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Ropchan
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Labaree
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Carson
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiyun Huang
3Department of Radiology and Biomedical Imaging PET Center, Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

499

Objectives: The M1 muscarinic acetylcholine receptor (M1 mAChR) is an important therapeutic target for Alzheimer’s disease and other neurodegenerative disorders. A novel PET radiotracer, 11C-LSN3172176, was developed to quantify M1 mAChR, and was previously shown to have favorable kinetics and high specific binding in monkey studies. The aim of this work was to evaluate modeling methods and test-retest variability of 11C-LSN3172176 in humans.

Methods: Six healthy subjects (3M/3F) completed a test-retest protocol. The test and retest scans were 5.8 ± 0.9 hours apart. An additional four healthy subjects (3M/1F) completed a scopolamine blocking protocol. The blocking scan was conducted 24 h after a scopolamine patch was placed. Acquisitions were 2-hour dynamic scans with an HRRT after injection of 11C-LSN3172176. Arterial blood samples were collected for measurement of tracer free fraction and the arterial input function. Using the AAL template and individual MR images, regions of interest (ROIs) were defined including striatum, neocortical regions, and cerebellum, to generate time-activity curves (TACs). Regional distribution volumes (VT) and binding potential (BPND) were calculated using one- and two-tissue compartment models (1TC and 2TC) and multilinear analysis-1 (MA1). The simplified reference tissue model (SRTM) was also used to estimate BPND. The cerebellum was used as a reference region, as it was the region with the lowest uptake and preclinical studies showed little to no specific binding. The absolute test-retest variability (aTRV) of VT and BPND were calculated as 100 [asterisk] |test - retest| / ((test + retest) / 2). M1 mAChR occupancy by scopolamine and non-displaceable distribution volume (VND) were estimated from the occupancy plot.

Results: Highest uptake of 11C-LSN3172176 was seen in the striatum, followed by neocortical regions, with lowest uptake in the cerebellum. Regional TACs were fitted well with all models, with a slight lack of fit for 1TC and MA1. Although the 2TC fits were good, the 2TC parameters often could not be reliably estimated (relative standard error of VT > 10% in 75% of fits) due to numerical identifiability problems. 1TC mean K1 values (mL/cm3/min) ranged from 0.18 (centrum semiovale) to 0.49 (putamen). 1TC mean VT values (mL/cm3) ranged from 5.0 (cerebellum) to 48.7 (ventral striatum). There was an excellent correlation of VT between 2TC vs. 1TC (VT (1TC) = 1.00[asterisk]VT (2TC) - 1.07, R2 = 0.99) after excluding estimates with large standard errors. MA1 VT values (t[asterisk]=10 min) matched well with those of 1TC (VT (MA1, t[asterisk]=10 min) = 1.00[asterisk]VT (1TC) + 0.17, R2 = 1.00). SRTM BPND values were well correlated with those from 1TC, but were slightly underestimated (BPND (SRTM) = 0.90[asterisk]BPND (1TC) + 0.17, R2 = 0.97). The aTRV of VT (1TC) was excellent (mean: 4%, range: 1-7%) in all regions. The aTRV of BPND (1TC) was also excellent (mean: 6%, range: 4-10%), but the aTRV of BPND (SRTM) was somewhat higher (mean: 9%, range: 5-13%). In occupancy plots for the scopolamine study, the striatum and pallidum regions followed a different regression line than the other regions. Mean occupancy values were 44 ± 7% (striatum and pallidum) and 31 ± 8% (other regions), with mean VND of 5.2 ± 0.7 mL/cm3, which was similar to the cerebellum VT (mL/cm3) values (baseline, 4.9 ± 0.5; blocking, 5.1 ± 0.5). Regional differences in occupancy may be attributable to differences in regional acetylcholine concentrations. Conclusion: The 1TC and MA1 are appropriate models for analysis of 11C-LSN3172176 imaging data. The cerebellum appears to be a suitable reference region given its lowest VT and negligible change in VT between baseline and blocking scans. SRTM is also a useful alternative model for analysis. 11C-LSN3172176 brain PET showed excellent test-retest variability and thus this tracer is likely to be highly useful for quantification of M1 ACh receptors in humans. Research Support: Eli Lilly and Company

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Kinetic modeling and test-retest variability of the M1 muscarinic acetylcholine receptor PET radiotracer 11C-LSN3172176 in humans
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Kinetic modeling and test-retest variability of the M1 muscarinic acetylcholine receptor PET radiotracer 11C-LSN3172176 in humans
Mika Naganawa, Nabeel Nabulsi, Shu-fei Lin, Lawrence Slieker, Adam Schwarz, Nancy Kant, Hong Gao, Jim Ropchan, David Labaree, Richard Carson, Yiyun Huang
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 499;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Kinetic modeling and test-retest variability of the M1 muscarinic acetylcholine receptor PET radiotracer 11C-LSN3172176 in humans
Mika Naganawa, Nabeel Nabulsi, Shu-fei Lin, Lawrence Slieker, Adam Schwarz, Nancy Kant, Hong Gao, Jim Ropchan, David Labaree, Richard Carson, Yiyun Huang
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 499;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Instrumentation & Data Analysis Track

  • Deep Learning Based Kidney Segmentation for Glomerular Filtration Rate Measurement Using Quantitative SPECT/CT
  • Comparison of 22 partial volume correction methods for amyloid PET imaging with 11C-PiB
  • The Benefit of Time-of-Flight in Digital Photon Counting PET Imaging: Physics and Clinical Evaluation
Show more Instrumentation & Data Analysis Track

Kinetic Modeling of Brain PET Studies

  • A comparison of kinetic models for PET imaging of cortical dopamine release induced by a task.
  • Direct Parametric Reconstruction for Improved Characterization of Neurotransmitter Release using Dynamic PET
Show more Kinetic Modeling of Brain PET Studies

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire